Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma

• Published in: World journal of gastroenterology : WJG Vol. 30; no. 19; pp. 2575 - 2602
• Main Authors: Peng, Tian, Sun, Fang, Yang, Jia-Chun, Cai, Mei-Hong, Huai, Man-Xiu, Pan, Jia-Xing, Zhang, Fei-Yu, Xu, Lei-Ming
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 21.05.2024
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - immunology; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Animals; Basic Study; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - immunology; Carcinoma, Pancreatic Ductal - mortality; Carcinoma, Pancreatic Ductal - pathology; Carcinoma, Pancreatic Ductal - therapy; Cell Line, Tumor; Cell Proliferation - genetics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lactic Acid - metabolism; Male; Monocarboxylic Acid Transporters - genetics; Monocarboxylic Acid Transporters - metabolism; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - immunology; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Prognosis; Protein Processing, Post-Translational; Symporters - genetics; Symporters - metabolism; Transcriptome; Tumor Microenvironment - immunology; Pancreatic adenocarcinoma; Prognosis; Tumor microenvironment; Immunotherapy; Lactylation
• ISSN: 1007-9327; 2219-2840; 2219-2840
• DOI: 10.3748/wjg.v30.i19.2575

Lactate, previously considered a metabolic byproduct, is pivotal in cancer progression and maintaining the immunosuppressive tumor microenvironment. Further investigations confirmed that lactate is a primary regulator, introducing recently described post-translational modifications of histone and non-histone proteins, termed lysine lactylation. Pancreatic adenocarcinomas are characterized by increased glycolysis and lactate accumulation. However, our understanding of lactylation-related genes in pancreatic adenocarcinomas remains limited. To construct a novel lactylation-related gene signature to predict the survival of patients with pancreatic cancer. RNA-seq and clinical data of pancreatic adenocarcinoma (PDAC) were obtained from the GTEx (Genotype-Tissue Expression) and TCGA (The Cancer Genome Atlas) databases Xena Explorer, and GSE62452 datasets from GEO. Data on lactylation-related genes were obtained from publicly available sources. Differential expressed genes (DEGs) were acquired by using R package "DESeq2" in R. Univariate COX regression analysis, LASSO Cox and multivariate Cox regressions were produced to construct the lactylation-related prognostic model. Further analyses, including functional enrichment, ESTIMATE, and CIBERSORT, were performed to analyze immune status and treatment responses in patients with pancreatic cancer. PDAC and normal human cell lines were subjected to western blot analysis under lactic acid intervention; two PDAC cell lines with the most pronounced lactylation were selected. Subsequently, RT-PCR was employed to assess the expression of LRGs genes; SLC16A1, which showed the highest expression, was selected for further investigation. SLC16A1-mediated lactylation was analyzed by immunofluorescence, lactate production analysis, colony formation, transwell, and wound healing assays to investigate its role in promoting the proliferation and migration of PDAC cells. validation was performed using an established tumor model. In this study, we successfully identified 10 differentially expressed lactylation-related genes (LRGs) with prognostic value. Subsequently, a lactylation-related signature was developed based on five OS-related lactylation-related genes ( and ) using Lasso Cox hazard regression analysis. Subsequently, we evaluated the clinical significance of the lactylation-related genes in pancreatic adenocarcinoma. A comprehensive examination of infiltrating immune cells and tumor mutation burden was conducted across different subgroups. Furthermore, we demonstrated that SLC16A1 modulates lactylation in pancreatic cancer cells through lactate transport. Both and experiments showed that decreasing SLC16A1 Level and its lactylation significantly inhibited tumor progression, indicating the potential of targeting the SLC16A1/Lactylation-associated signaling pathway as a therapeutic strategy against pancreatic adenocarcinoma. We constructed a novel lactylation-related prognostic signature to predict OS, immune status, and treatment response of patients with pancreatic adenocarcinoma, providing new strategic directions and antitumor immunotherapies.